Business Wire

Thales Launches File Activity Monitoring (FAM) to Strengthen Real-Time Visibility and Control Over Unstructured Data

10.6.2025 09:00:00 CEST | Business Wire | Press Release

Share

Thales today announced the launch of Thales File Activity Monitoring, a powerful new capability within the Thales CipherTrust Data Security Platform that enhances enterprise visibility and control over unstructured data, enabling organizations to monitor file activity in real time, detect misuse, and ensure regulatory compliance across their entire data estate. As the only integrated platform provider that secures structured and unstructured data, Thales provides comprehensive monitoring and auditability for data types that were previously difficult to track.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610528685/en/

©Thales

In today’s evolving threat landscape, organizations must gain tighter control over unauthorized access and misuse of unstructured data, which according to IDC represents 90% of all worldwide data. File Activity Monitoring enables security teams to analyze and monitor the activity of unstructured data, including unexpected copying, downloading, and sharing of files such as emails, chat logs, media files, and application logs that can contain sensitive data. Real-time alerts, analytics, and encryption tracking further accelerate threat insights and protect sensitive data across the enterprise. This reduces exposure risks, supports compliance with standards like GDPR, HIPAA, and PCI DSS, and strengthens organizations’ overall data security posture.

“Thales’ innovative approach to File Activity Monitoring tackles key challenges like blind spots in hybrid environments, offering real-time visibility and smart anomaly detection — a potential game-changer for teams overwhelmed by false positives. By striking the right balance of depth and simplicity, FAM shows promise in helping us strengthen the SOC without added complexity. With tighter SIEM integration, it can sharpen response and let teams focus on what matters most. We’re excited to see how FAM evolves and enhances our data security,” Leila KUNTAR, Principal Information Security Engineer, Amadeus, said.

“As unstructured data grows rapidly across distributed environments, organizations need more integrated ways to track and safeguard their most sensitive information,” Todd Moore, Vice President of Data Security Products at Thales, said. “With File Activity Monitoring, Thales reinforces its leadership in enterprise data security by delivering real-time insight, intelligent automation, and unified visibility through a single, powerful platform.”

Thales has been a leader in digital security for decades in structured database activity. Building on this extensive expertise, customers can expect the same world-class experience that they’ve had with Thales, now extended to encompass unstructured data protection.

File Activity Monitoring strengthens DSPM by enabling security teams to:

  • Discover, classify, observe, and control sensitive data across on-premises, hybrid, and multicloud environments
  • Pinpoint where sensitive data resides, who has access, and whether it's properly secured, in real time, allowing detection of suspicious behavior including unauthorized copying, downloading, or sharing
  • Transform static classification into dynamic risk intelligence through behavioral context
  • Apply strong encryption and other remediation techniques, including reconstruction of incidents quickly with audit logs in the event of a breach or policy violation and enabling strong encryption, to protect compromised or at-risk data

Built-in GenAI tools simplify audits, boost response, and cut complexity

To further simplify compliance and security operations, File Activity Monitoring includes a Generative AI-powered Data Security Assistant. This integrated chatbot helps teams query audit data, generate custom reports, and streamline compliance workflows, reducing the burden on IT and security professionals and making it easier to meet regulatory obligations.

“As technology evolves rapidly, our controls must be flexible enough to keep pace without adding complexity,” Moore said. “Automation and intelligence help overwhelmed security teams scale operations and focus on what matters most. With tools like our chatbot, they can ask natural language questions and get instant, actionable answers, accelerating response times and improving operational efficiency.”

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.

The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.

Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610528685/en/

Contacts

Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye